New Delhi: Bharat Biotech’s nasal vaccine can prove to be a game-changer in the fight against Coronavirus. This Hyderabad-based drug maker has got approval for the Phase III clinical trial of Intranasal COVID-19 Vaccine as a booster dose.
Dr. Sanjay Rai, senior epidemiologist of Delhi-based All India Institute of Medical Sciences (AIIMS), said that if this vaccine provides mucosal immunity in clinical trials, then it will be a big success. In such a situation, this vaccine can prove to be a game-changer in the fight against the epidemic.
33 vaccines, but none effective
Senior epidemiologist at AIIMS, Dr. Sanjay Rai told news agency ANI that if this vaccine provided mucosal immunity, it would be a great achievement for mankind. There are 33 vaccines worldwide, but none are effective in preventing infection. We are hoping that this vaccine will provide mucosal immunity, which can prevent the epidemic from progressing further.
This expectation expressed from the budget
The senior epidemiologist of AIIMS said that the budget to be presented by the government should contain announcements related to strengthening of public health systems at primary, secondary and tertiary levels, because it is very important. He said that this is not the last pandemic. We should be prepared for future pandemics. Not only this, we need to strengthen the public health system to deal with the coming threats.
Trial will be done at 9 places
The Drugs Controller General of India (DCGI) has given approval for Phase III clinical trial of Bharat Biotech’s intranasal COVID-19 vaccine as a booster dose at Hyderabad. The trial will be done at nine different places. Significantly, earlier this month, the Subject Expert Committee (SEC) of DCGI gave in-principle approval to Bharat Biotech for the trial of its intranasal vaccine (BBV154).